• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12B filed by Kadmon Holdings, Inc.

    11/19/21 4:01:10 PM ET
    $KDMN
    Major Pharmaceuticals
    Health Care
    Get the next $KDMN alert in real time by email
    15-12B 1 brhc10030954_15-12b.htm 15-12B
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    FORM 15


    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
     
    Commission File Number 001-37841


    KADMON HOLDINGS, INC.
     (Exact name of registrant as specified in its charter)


    450 East 29th Street
    New York, NY 10016
    (833) 900-5366
     (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
     
    Common Stock, $0.001 Par Value Per Share
    (Title of each class of securities covered by this Form)
     
    None
    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)


    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
    Rule 12g-4(a)(1)
     
    ☒
    Rule 12g-4(a)(2)
     
    ☐
    Rule 12h-3(b)(1)(i)
     
    ☒
    Rule 12h-3(b)(1)(ii)
     
    ☐
    Rule 15d-6
     
    ☐
    Rule 15d-22(b)
     
    ☐
     
    Approximate number of holders of record as of the certification or notice date: 1
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, Kadmon Holdings, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

       
    Kadmon Holdings, Inc.
         
    Date: November 19, 2021
    By:
    /s/ Gustavo Pesquin
       
    Name: Gustavo Pesquin
       
    Title: Chief Executive Officer



    Get the next $KDMN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KDMN

    DatePrice TargetRatingAnalyst
    9/14/2021$13.00 → $9.50Buy → Neutral
    Mizuho
    9/9/2021$10.00 → $9.50Buy → Hold
    Jefferies
    7/19/2021$8.00 → $9.00Outperform
    Oppenheimer
    More analyst ratings

    $KDMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Flowers Cynthia Louise gifted 20,150 shares and returned $103,075 worth of shares to the company (10,850 units at $9.50), closing all direct ownership in the company

      4 - Kadmon Holdings, Inc. (0001557142) (Issuer)

      11/9/21 5:41:38 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Cohen David E

      4 - Kadmon Holdings, Inc. (0001557142) (Issuer)

      11/9/21 5:37:34 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Ryan John L

      4 - Kadmon Holdings, Inc. (0001557142) (Issuer)

      11/9/21 5:41:04 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care